ArticleDiscover oncology2026
USP14 promotes epithelial-mesenchymal transition and functions as a multifaceted biomarker in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Ubiquitin-specific protease 14 (USP14) is highly expressed in various tumors and functions as a critical regulator of proteasomal protein degradation. However, a comprehensive understanding of clinical relevance, prognostic value, and immunotherapy prediction of USP14 in lung adenocarcinoma (LUAD) has yet to be established. USP14 expression was found upregulated and related with poor survival in LUAD using transcriptome and proteome data from TCGA and PDC databases. Then functional and rescue experiments showed that USP14 increases the ability of LUAD cells to migrate, invade, and undergo epithelial-mesenchymal transition (EMT) through Wound-healing assays, Transwell assays and western blot. Furthermore, enrichment analysis positioned USP14 as a positive regulator of the PI3K-AKT-mTOR signaling pathway. Moreover, immune cell infiltration analysis in relation to USP14 expression reveals its association with immune evasion and low response of immunotherapy. In conclusion, USP14 contributes to LUAD development through three key mechanisms: suppressing immune responses, promoting EMT, and activating the Akt signaling pathway. Our research establishes USP14 as a multifaceted biomarker and immunotherapy target. These findings provide a deeper understanding of USP14's crucial role in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.